Dawaa Reference

Clinical reference

Uncertain or in-situ neoplasm of the urinary tract

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources3 sources

Bladder Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK536923/ · ICPC-3 (WONCA International Classification of Primary Care, 3rd edition) class UD29 - condition scope only, no dose · No dose - referral pathway, no medicine given in primary care

Verified against1 document
  • No dose - referral pathway, no medicine given in primary care

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (7)

  • Blood in the urine, visible or microscopic, is the usual first symptom [blood in the urine]
  • Over a third with visible blood, and just above 10% with microscopic blood, prove to have bladder cancer
  • Less often: painful voiding, more frequency, a pelvic mass, tiredness or weight loss [fatigue · pelvic mass · urinary frequency · weight loss]
  • Irritative voiding is how 80% of in-situ disease presents, doubling its likelihood alongside microscopic blood
  • Stones, urine infection and prostatic enlargement produce those same irritative symptoms
  • Mainly a disease of adults aged 60 and older
  • Smoking predisposes strongly, and 10 pack-years or more already lifts risk markedly

Signs — what you find (8)

  • Unexplained haematuria warrants full history and examination, seeking cancer risk and other bleeding sources alike [bleeding · blood in the urine]
  • In women, examine the pelvis and inspect vulva, introitus and the area around the urethra
  • Being on an anticoagulant does not shorten the work-up
  • Suspect kidney disease as the source given proteinuria, dysmorphic red cells, casts, or renal failure [proteinuria]
  • Risk rises with a long-term catheter, cyclophosphamide or ifosfamide, irritative voiding, or past pelvic radiotherapy
  • Family history of bladder cancer, Lynch, Peutz-Jeghers or Cowden syndrome also raises it
  • So does chemical exposure: aromatic amines, arsenic, benzene, formaldehyde, nitrosamine, petrochemicals, rubber
  • Where Schistosoma haematobium is endemic it predisposes to squamous cell carcinoma

Tests (12)

  • High risk, or failing to qualify as low or intermediate, means CT urogram and cystoscopy
  • High risk means visible blood, age 60 or older, smoking >30 pack-years, or >25 RBC/HPF
  • Ultrasound is the weaker test and overlooks small tumours, cystic lesions and in-situ disease
  • Delayed films show filling defects, and one in the upper tract then needs ureteroscopy
  • Where IV contrast is barred by poor kidney function or allergy, use an MRI urogram
  • Repeat cystoscopy, photodynamic enhancement, or urine markers have a place in high-risk or equivocal cases
  • In-situ disease looks like a flat, red, velvety patch, so close to inflammation that it is very hard to call
  • Because it hides as inflammation, inflamed bladder lesions merit biopsy or cautery during resection
  • Take random mapping biopsies when cytology is positive, or the growth looks solid rather than frond-like
  • A positive cytology can be trusted, but a negative one misses many cancers, low-grade ones especially
  • Cytology helps find and follow in-situ disease that cystoscopy can pass over
  • Enhanced cystoscopy techniques pick up in-situ and otherwise invisible surface tumours well

If not this — what else fits (12)

  • Benign prostatic hyperplasia
  • A bladder wall thickened by obstruction or by infection
  • Gynaecological and other pelvic cancers
  • Bleeding arising outside urothelial cancer altogether
  • Haemorrhagic cystitis
  • Interstitial cystitis
  • Urinary stone disease
  • Overactive bladder
  • Prostatitis
  • Cystitis following radiotherapy
  • A renal mass or renal tumour
  • Urinary tract infection

SourceStatPearls "Bladder Cancer" - disease-level clinical article

Presentation findings are traced to the source above.

1

NO DRUG THERAPY IN PRIMARY CARE (REFERRAL & ADVICE)

1st line
Adult dose and duration

Carcinoma in situ of the urinary bladder is a high-grade, flat urothelial malignancy that frequently presents with persistent irritative voiding symptoms such as dysuria, urgency, or hematuria without infection. Primary care physicians should urgently refer any patient with unexplained, sterile irritative voiding symptoms or hematuria to urology for cystoscopy and urinary cytology. No pharmacological treatment is initiated in primary care; intravesical BCG immunotherapy or surgical management is directed by urology. - Refer, with advice

Paediatric dose

Children follow the same pathway: recognise and refer. No primary-care medicine is implied.

Dose source

No dose - referral pathway, no medicine given in primary care

Why

Carcinoma in situ of the urinary bladder is a high-grade, flat urothelial malignancy that frequently presents with persistent irritative voiding symptoms such as dysuria, urgency, or hematuria without infection. Primary care physicians should urgently refer any patient with unexplained, sterile irritative voiding symptoms or hematuria to urology for cystoscopy and urinary cytology. No pharmacological treatment is initiated in primary care; intravesical BCG immunotherapy or surgical management is directed by urology.

Cautions
  • Any suspicious urinary tract lesion needs prompt specialist evaluation given its malignant potential.
  • No medicine is prescribed for this in primary care - this entry is for recognition and referral. Anything given is decided by the service it is referred to.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.